<DOC>
	<DOCNO>NCT00644904</DOCNO>
	<brief_summary>Vitamin D likely play role geography Multiple Sclerosis ( MS ) , patient risk MS relatively low Vitamin D level compare normal counterpart . This trial examine safety high dose oral Vitamin D3 titrate maximum 40,000 IU per day 12 month period . Fifty patient match MS non-MS characteristic divide two group : one group receive high dose Vitamin D regimen , restrict maximum 4000 IU per day . The hypothesis patient MS tolerate seemingly high dos Vitamin D3 without adverse event and/or calcium-related abnormality . It also hypothesize receive high dos demonstrate improve relapse disability status compare control , treatment group show improve marker bone health immune indicator reduce inflammation .</brief_summary>
	<brief_title>Safety Trial High Dose Oral Vitamin D3 With Calcium Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Clinically definite MS Age 1855 EDSS 06.5 EDSS = &gt; 7.0 Current Vitamin D3 use &gt; 4000 IU/d Baseline ( 25 ( OH ) D ) level &lt; 20 mmol/L ( frank deficiency ) &gt; 150 mmol/L Pregnancy inability/unwillingness use contraception History cardiac arrhythmia History renal disease nephrolithiasis History granulomatous disease lymphoma Relapse activity steroid use past 60 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Safety</keyword>
</DOC>